Drug intelligence / Profile preview

Alpha-201 + interleukin-12 + interleukin-15

Development stage: Unknown
Lead developer: Amgen
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intratumoral

Overview

Alpha-201 + interleukin-12 + interleukin-15 (also known as AMG 199) is an investigational oncolytic immunotherapy developed by Amgen. It consists of a second-generation, modified herpes simplex virus type 1 (HSV-1) vector engineered to selectively replicate within and lyse tumor cells. Beyond its direct oncolytic activity, the virus is designed to deliver and express two potent proinflammatory cytokines, interleukin-12 (IL-12) and interleukin-15 (IL-15), directly within the tumor microenvironment. IL-12 promotes a Th1 immune response and activates cytotoxic T cells and natural killer (NK) cells, while IL-15 supports the survival and proliferation of these effector cells. By combining local viral-induced cell death with the targeted expression of these cytokines, Alpha-201 aims to stimulate a systemic, durable anti-tumor immune response, potentially overcoming resistance to existing immunotherapies in patients with advanced solid tumors.

Other names: Alpha-201-IL12-IL15Alpha201-IL12-IL15Alpha 201-IL12-IL15oHSV-IL12-IL15oHSV-IL-12-IL15oHSV-IL 12-IL15

Targets

IL-12R (Interleukin-12 receptor)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)

Beyond the preview

Go deeper on Alpha-201 + interleukin-12 + interleukin-15.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-201 + interleukin-12 + interleukin-15.

Explore the full profile